Post-stent chest pain, revisited
Heart Sisters
JULY 28, 2024
Heart patients with persistent or recurrent post-stent chest pain present “an unmet clinical need”, according to the European Journal of Cardiology.
Sun.Jul 28, 2024
119 
Antiretroviral Abacavir Linked With Cardiovascular Events in REPRIEVE Trial
Med Page Today
JULY 28, 2024
(MedPage Today) -- People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of the REPRIEVE trial. Past use of abacavir increased.
Sexual Dysfunction Common Among Patients with Psoriatic Arthritis
HCPLive
JULY 28, 2024
Most men (91.7%) and women (72.7%) with psoriatic arthritis exhibited sexual dysfunction.
Edwards Acquires JenaValve and Endotronix, Expands into Aortic Regurgitation and Heart Failure
CardiacWire
JULY 28, 2024
Edwards Lifesciences is going all-in on structural heart and heart failure, acquiring aortic valve-maker JenaValve Technology and implantable heart failure monitor company Endotronix for $1.2B and up to $445M in milestone payments. These two acquisitions could impact Edwards’ structural heart and heart failure portfolios in unique and meaningful ways… JenaValve’s Trilogy TAVR system doesn’t yet have FDA approval, but is CE Marked for both aortic regurgitation and aortic stenosis, which is notabl
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Potential new therapeutic target for HFpEF
Nature Reviews - Cardiology
JULY 28, 2024
Nature Reviews Cardiology, Published online: 29 July 2024; doi:10.1038/s41569-024-01066-2 A new small-molecule inhibitor of vasohibins reduces myocardial stiffness and improves diastolic relaxation in a rat model of HFpEF.
Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists
Cardiovascular Diabetology
JULY 28, 2024
Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) have demonstrated efficacy in improving mortality and cardiovascular (CV) outcomes. However, the impact of GLP-1RAs therapy on cardiorenal outcomes of diabe.
Sign up to get articles personalized to your interests!
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
More Trending
Ultrasound parameters of arteries and heart in normal fetuses
Cardiovascular Ultrasound
JULY 28, 2024
Currently, no normal ultrasound data of the fetuses during the 20–40 gestation have been obtained for references of fetal growth and development. If such ultrasound data existed for prenatal diagnosis of possi.
Extensive myocardial calcifications: a systematic literature review of a rare pathological phenomenon
Frontiers in Cardiovascular Medicine
JULY 28, 2024
IntroductionMyocardial calcifications (MC) represent a relatively rare pathological process, which may accompany different cardiovascular conditions and can be broadly categorized as dystrophic or metastatic. Myocardial infarction (MI) has been traditionally regarded as the main cause of MC overall; however, no updated comprehensive data on the relative incidence of different forms of MC is available.
Long-term management of recurrent in-stent restenosis
Cardiology Update
JULY 28, 2024
A recent study published in JACC: Cardiovascular Interventions has provided new insights into the long-term management of patients suffering from recurrent in-stent restenosis (ISR), a condition presenting notable challenges in cardiovascular treatment. With minimal data and guidelines available for repeat percutaneous coronary interventions (PCI), this research offers valuable guidance for clinicians.
Delgocitinib Cream Effective Over 16 Weeks for Chronic Hand Eczema
HCPLive
JULY 28, 2024
These findings support delgocitinib’s clinical benefit as a possible medication option for individuals with moderate to severe chronic hand eczema.
IGFBP7: From Senescence Biomarker to a Vaccine for Heart Failure
Circulation
JULY 28, 2024
Circulation, Volume 150, Issue 5 , Page 390-392, July 30, 2024.
Lessons from PROMINENT and prospects for pemafibrate
Cardiovascular Diabetology
JULY 28, 2024
The neutral result of the PROMINENT trial has led to questions about the future for pemafibrate. This commentary discusses possible reasons for the lack of benefit observed in the trial. There were, however, i.
Myocardial Regeneration: Feasible or Fantasy?
Circulation
JULY 28, 2024
Circulation, Volume 150, Issue 5 , Page 347-349, July 30, 2024.
Antithrombotic treatment regimens in patients undergoing percutaneous coronary revascularization requiring oral anticoagulation: what real-world evidence shows us
Journal of Cardiovascular Pharmacology
JULY 28, 2024
An abstract is unavailable. This article is available as a PDF only.
Correction to: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Circulation
JULY 28, 2024
Circulation, Volume 150, Issue 5 , Page e105-e105, July 30, 2024.
Left ventricular mass as a modulator of ventricular arrhythmia risk and sex differences after CRT for nonischemic cardiomyopathy and LBBB
HeartRhythm
JULY 28, 2024
The risk of ventricular arrhythmias (VAs) after cardiac resynchronization therapy (CRT) has been associated with ischemic disease/scar, sex, and possibly left ventricular mass (LVM).
Letter by Katsouras Regarding Article, “Prognostic Significance of Different Ventricular Ectopic Burdens During Submaximal Exercise in Asymptomatic UK Biobank Subjects”
Circulation
JULY 28, 2024
Circulation, Volume 150, Issue 5 , Page e102-e103, July 30, 2024.
Ophthalmologists, Patients Hesitate to Switch to Anti-VEGF Biosimilars
HCPLive
JULY 28, 2024
Hesitancy with anti-VEGF biosimilars was identified in a survey among both ophthalmologists and patients with nAMD in Canada.
Response by Lambiase and van Duijvenboden to Letter Regarding Article, “Prognostic Significance of Different Ventricular Ectopic Burdens During Submaximal Exercise in Asymptomatic UK Biobank Subjects”
Circulation
JULY 28, 2024
Circulation, Volume 150, Issue 5 , Page e104-e104, July 30, 2024.
Let's personalize your content